

RESEARCH

Open Access



Plasma exosomes lncRNA-miRNA-mRNA network construction and its diagnostic efficacy identification in first-episode schizophrenia

Xinzhe Du^{1,2}, Jinzhi Lv³, Jianping Feng¹, Xinrong Li^{1,2}, Yao Gao^{1,2}, Xiao Wang^{1,2}, Wentao Zhao^{1,2}, Zhiyong Ren⁴, Ruifang Zhang⁴, Xiaohua Cao^{1,2}, Sha Liu^{1,2*} and Yong Xu^{1,5*}

Abstract

Background The exosomal lncRNA-miRNA-mRNA networks in first episode schizophrenia (FOS) have not reported yet. This study examined the lncRNA, miRNA and mRNA expression level in exosome derived from first episode schizophrenia (FOS) patients, and explored the the potential of exosomes as biomarkers for schizophrenia.

Methods We recruited 10 FOS patients and healthy controls (HCs) respectively, examined the lncRNA, miRNA and mRNA expression level of plasma exosome by high throughput sequencing, constructed lncRNA-miRNA-mRNA network, and performed correlation analysis, GO and KEGG pathway analysis, PPI network construction and ROC analysis.

Results There were 746 differently expressed lncRNA, 22 differently expressed miRNA, and 2637 differently expressed mRNA in plasma exosome in FOS compared with HCs. Then we constructed ceRNA network consisting of 8 down-regulated lncRNA, 7 up-regulated miRNA and 65 down-regulated mRNA, and 1 up-regulated lncRNA, 1 down-regulated miRNA and 4 up-regulated mRNA. The expression level of 1 lncRNA and 7 mRNA in exosomal network were correlated with PANSS score. GO and KEGG pathway analysis showed that 4 up-regulated mRNAs were enriched in neuropsychiatric system function. Down-regulated mRNA EZH2 and SIRT1 were identified as hub gene. Finally, we detected the ROC curve of ENSG00000251562, miR-26a-5p, EZH2, miR-22-3p, SIRT1, ENSG00000251562—miR-26a-5p—EZH2, ENSG00000251562—miR-22-3p—SIRT1, and found that the AUC of ceRNA network was higher than lncRNA, miRNA and mRNA alone.

Conclusion We constructed the lncRNA-miRNA-mRNA network in exosome derived from FOS plasma, and found that lncRNA-miRNA-mRNA network has potential as biomarkers for FOS.

Keywords Schizophrenia, Exosome, lncRNA, miRNA, mRNA

*Correspondence:

Sha Liu

liusha@sxmu.edu.cn

Yong Xu

xuyongsmu@vip.163.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Schizophrenia (SZ) is one of the most common severe mental disorders in clinic, with a lifetime prevalence rate of about 1%. About 5–6% of patients with SZ die of suicide, and their life expectancy is reduced by about 10–20 years worldwide [1]. The 2019 Chinese Mental Health Survey showed that the lifetime prevalence of SZ in China has been increasing in recent years [2]. SZ often occurs in adolescence and early adulthood, is a disease with high recurrence rate and disability rate, easily leading to mental decline and disability [3], which brings heavy burden to patients, their families and even the whole society. At present, the diagnosis of SZ is still mainly based on clinical interviews and observations. These description methods are subjective and variable, which may lead to delayed diagnosis or misdiagnosis. Therefore, it is meaningful to find more objective diagnosis methods such as biomarkers for effective treatment of SZ.

Biomarkers refer to indicators that play an indicative role in biological responses, pathological processes, or pharmacological responses to therapeutic interventions, and have the characteristics of objective detection and evaluation. Message RNA (mRNA) and non-coding RNA in peripheral blood has been reported as a biomarker of SZ [4]. The mRNA, selenium-binding protein 1 (SELENBP1) and mitochondrial complex I, and the microRNA (miRNA) has-miR-34a and has-miR-432, were potentially useful biomarker for SZ [5]. Long non-coding RNAs (lncRNAs) showed aberrant expression in SZ [6] and some lncRNA, such as XIST, could be regarded as candidates for biomarker [7]. lncRNAs could act as endogenous molecular sponges of miRNAs to indirectly regulate mRNA expression, which is also known as ceRNA (competitive endogenous RNA) network [8]. In recent years, many studies have shown that dysregulation of the lncRNA-miRNA-mRNA network was related to the pathogenesis of many diseases such as cancers [9]. Nevertheless, the potential roles of lncRNA-miRNA-mRNA in SZ has not been explored yet.

Exosomes are membrane vesicles with a diameter of 30–150 nm, wrapped with protein and nucleic acid (mRNA, miRNA, lncRNA, etc.) and other biomolecules. Neurons, microglia, astrocytes, etc., can secrete exosomes and absorb exosomes secreted by other cells [10]. Exosomes secreted by nerve cells are involved in a variety of physiological processes, including synaptic plasticity, nerve regeneration, and inflammatory responses, and played an important role in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease [11, 12]. Recently many studies suggested that exosomes are promising biomarkers for SZ and

depression [13, 14]. However, lncRNA-miRNA-mRNA in SZ exosomes has not been reported.

In this study, we used high-throughput sequencing to detect the expression levels of lncRNA, miRNA and mRNA in plasma exosomes of HCs and FOS patients, and combined with bioinformatics methods to construct lncRNA-miRNA-mRNA networks, correlation analysis of lncRNAs with PANSS score, miRNAs and mRNAs in network, GO and KEGG pathway and PPI network of mRNAs in network were performed. Finally, the sensitivity of lncRNA-miRNA-mRNA networks as diagnostic markers was identified to provide new ideas for the diagnosis of diseases (Fig. 1).

Methods

Subjects

Ten first episode schizophrenic (FOS) were recruited from First Hospital of Shanxi Medical University according to the following criteria: 1. diagnosed as SZ according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5), 2. the first episode of SZ and no history of drug treatment, 3. The Han nationality, 4. the score of PANSS ≥ 60 . 10 healthy controls (HCs) were recruited from the community. They were selected to match to the FOS for gender, age and years of education. Those who had any prior medical diagnosis, neuropsychiatric disorders, substance abuse were excluded.

This study was approved by the Research Ethics Committee of the First Hospital of Shanxi Medical University, and written informed consents were obtained from all




Fig. 1 The flowchart of this study

participants. All methods were performed in accordance with the relevant guidelines and regulations.

Exosome isolation

About 5 ml of plasma was isolated from 10 ml of peripheral blood. The plasma exosome was extracted from 5 ml plasma of participants. The exosomes were isolated using the exoEasy Maxi Kit (Qiagen) following the manufacturer's protocol.

RNA isolation and RNA sequencing

Exosomes performed RNA sequencing at the Cloud-Seq Biotech Ltd. Co. (Shanghai, China). Total RNA was used for removing the rRNAs with NEBNext® rRNA Depletion Kit (New England Biolabs, Inc., Massachusetts, USA) following the manufacturer's instructions.

RNA libraries were constructed by using rRNA-depleted RNAs with TruSeq Stranded Total RNA Library Prep Kit (Illumina, USA) according to the manufacturer's instructions. Libraries were controlled for quality and quantified using the BioAnalyzer 2100 system (Agilent Technologies, USA). Library sequencing was performed on an illumina Novaseq 6000 instrument with 150 bp paired end reads. The RNA sequencing data were upload to GEO database (GSE228881, Token number: sfobcgaibvyrpgt).

LncRNA-miRNA-mRNA network construction

LncRNA target genes were predicted by the locations to nearby genes. MiRmap, micorT, miRanda, PicTar and TargetScan were used to predict miRNA-mRNA target relationship. Cytoscape was used for visualization of the network.

Correlation analysis

SPSS23 was used for correlation analysis between gene expression level and PANSS score, and partial correlation analysis was used for calculation after controlling age, sex and education level.

GO and KEGG pathway analysis and PPI network construction

GO function (including biological process (BP), molecular function (MF) and KEGG pathway analysis [15–17] by bioinformatics (<http://www.bioinformatics.com.cn>). GO and KEGG pathways with a *P*-value < 0.05 were supposed to be significantly enriched. Proteinprotein interaction (PPI) network was created by the Search Tool for the Retrieval of Interacting Genes database (STRING-Version 10.0, <http://stringdb.org>) with the interaction score > 0.4, and Cytoscape software was used to visualize and analyze the biological networks.

ROC analysis

The diagnostic efficacy of lncRNA, miRNA, mRNA and lncRNA-miRNA-mRNA network were examined by receiver operating characteristic (ROC) analysis. ROC curves was performed using the OmicStudio tools at <https://www.omicstudio.cn/tool/58>.

Statistical analysis

In demographic information, data were presented as mean ± standard deviation (SD). The significant differences were analyzed with SPSS version 23.0. Statistical analyses of age and education level which were normally distribution were performed using student's *t*-test. Statistical analysis of gender were performed using Chi-square test. Differentially expressed lncRNA, miRNA and mRNA between two groups were filtered by Fold Change (Fold Chang ≥ 2, log(FC) ≥ 1.0) and *P*-value (*P*-value ≤ 0.05). The significant differences were performed using student's *t*-test.

Results

Demographic information of study subjects

We recruited 10 FOS and 10 matched HCs. The age, sex, and education level of 10 FOS and 10 HCs showed no significant differences. The mean value of PANSS score for FOS was 75.6 (Table 1).

Identification of differentially expressed lncRNA, miRNA and mRNA in plasma exosome

To identify differentially expressed exosomal circRNAs, miRNAs and mRNAs in exosomes in SZ, we performed RNA sequencing on plasma exosomes from 10 FOS patients and 10 HCs. There were 385 up-regulated and 361 down-regulated lncRNA, 14 up-regulated and 8 down-regulated miRNA, 690 up-regulated and 1947 down-regulated mRNA (Fig. 2, Supplementary Table S1).

Construction lncRNA-miRNA and miRNA-mRNA network

Then, we constructed lncRNA-miRNA and miRNA-mRNA network based on differentially expressed lncRNAs, miRNAs and mRNAs. Firstly, the target lncRNAs and mRNAs of down-regulated miRNA were

Table 1 Demographics and clinical characters for HCs and FOS

	FOS (n = 10)	HCs (n = 10)	<i>P</i> -value
Age (years)	34.2 ± 12.01	33.6 ± 12.05	0.9124
Males (%)	50	50	1.0000
Education level (years)	10.9 ± 3.665	9.9 ± 3.178	0.5227
PANSS total scores	75.60 ± 18.63		




Fig. 2 Volcano plots of exosomal DE-lncRNAs (a), DE-miRNAs (b) and DE-mRNAs (c) in SZ. The red points indicate differentially expressed lncRNA, miRNA and mRNA

identified. There are 380 down-regulated miRNA targeted lncRNA. The venn map was used to analyze the intersection between DEMiRNA target lncRNA and DElncRNA, and 1 up-regulated lncRNA (Fig. 3c) were identified. According to 1 up-regulated lncRNA, 1 down-regulated miRNA were recognized reversely (Fig. 3d). There were 10 overlapped up-regulated mRNA between down-regulated miRNA targeted mRNA and up-regulated mRNA (Fig. 3a). According to these 10 up-regulated mRNA, 2 down regulated mRNA were recognized (Fig. 3b).

Subsequently, the target lncRNAs and mRNAs of up-regulated miRNA were identified. There were 670 up-regulated miRNA targeted lncRNA, and 10 down-regulated lncRNA were identified in venn map (Fig. 3e). According to these 10 down-regulated lncRNA, 9 up-regulated miRNA were recognized (Fig. 3f). There are 88 up-regulated miRNA targeted mRNA, and 87 down-regulated mRNA were identified in venn map (Fig. 3g). According to these 87 down-regulated mRNA, 8 up-regulated miRNA were recognized (Fig. 3h).

Construction lncRNA-miRNA-mRNA ceRNA network

Then we constructed the ceRNA network. Taking the intersection of 9 up-regulated miRNA in Fig. 3f and 8 up-regulated miRNA in Fig. 3g, and found 7 overlapped up-regulated miRNA, combining the interacted lncRNA and mRNA, then the ceRNA network including 8 down-regulated lncRNA, 7 up-regulated miRNA and 65 down-regulated mRNA were constructed which including 129 edges (Fig. 4). In the same way, the ceRNA network including 1 up-regulated lncRNA,


1 down-regulated miRNA and 4 up-regulated mRNA were constructed which including 5 edges (Fig. 4).

The gene expression level of exosomes ceRNA network correlated with the PANSS score

In order to explore the relationship between genes expression level in exosomal ceRNA network and clinical severity, the correlation between gene expression levels and PANSS scores including positive score, negative score, general psychopathology score and PANSS score (Sum of the first three values) was examined. In lncRNA, ENSG00000251562 was positively correlated with the negative score and PANSS score. None of miRNAs were associated with PANSS. In mRNA, BFAR and HECTD4 were positively correlated with negative score, general psychopathology score and PANSS score. CHORDC1 and POGK were positively correlated with negative score and PANSS score. PRPF38B, ULK1 were positively correlated with negative score. TRUB1 was negatively correlated with negative score (Table 2).

GO and KEGG pathway analysis of DEMRNA in ceRNA network

In order to explore the potential mechanisms of mRNA enriched in CeRNA network, GO and pathway enrichment analysis were performed. The down DEMRNA in BP were enriched in peptidyl-lysine modification, positive regulation of macroautophagy, response to leukemia inhibitory, cellular response to leukemia inhibitory factor, cellular response to leukemia inhibitory factor (Fig. 5a). The down regulated mRNA in MF were enriched in transcription coregulator activity, mRNA 5'-UTR binding, bHLH transcription factor binding, ubiquitin-like protein






Fig. 4 Construction of a lncRNA-miRNA-mRNA ceRNA network. lncRNA(down-regulated)-miRNA(up-regulated)-mRNA(down-regulated) regulatory network (left). The network consisting 8 lncRNA, 7 miRNA and 65 mRNA. lncRNA(up-regulated)-miRNA(down-regulated)-mRNA(up-regulated) regulatory network (right). The network consisting 1 lncRNA, 1 miRNA and 4 mRNA. The network was generated by Cytoscape. Down-regulated lncRNAs were represented by diamonds in light orange. Up-regulated lncRNAs were represented by diamonds in orange. Up-regulated miRNAs were represented by V-shape in light green. Down-regulated miRNAs were represented by V-shape in green. Down-regulated mRNAs were represented by circle in green purple. Up-regulated mRNAs were represented by circle in blue. Larger circles indicates more numbers of connections of genes

transferase activity, histone-lysine N-methyltransferase activity (Fig. 5b). As for the the KEGG analysis, the down-regulated mRNA were enriched in lysine degradation, ECM-receptor interaction, longevity regulating pathway, nucleocytoplasmic transport, AMPK signaling pathway, selenocompound metabolism (Fig. 5c).

The BP terms of up-regulated mRNA were enriched in peripheral nervous system neuron differentiation, peripheral nervous system neuron development, mechanosensory behavior, positive regulation of calcineurin-NFAT signaling cascade, positive regulation of calcineurin-mediated signaling (Fig. 5d). The MF terms of up-regulated mRNA were enriched in MAP kinase kinase activity, protein phosphatase binding, phosphatase binding and magnesium ion binding (Fig. 5e). By the KEGG analysis, the up-regulated mRNA were enriched in platinum drug resistance, TNF signaling pathway, sphingolipid signaling pathway, apoptosis (Fig. 5f)

PPI network construction and hub genes identification

In order to find out the functional association between the identified genes, the PPI network was constructed based on the STRING online database and visualized by Cytoscape software. The PPI network contained 19 nodes and 20 edges. According to the number of connection

indicated from Cytoscape's cytoHubba plugin, the EZH2(7) and SIRT1(6) were the identified as hub gene (Fig. 6), and were used in subsequently study.

Receiver operating characteristic analysis of lncRNA, miRNA and mRNA

In order to examine the diagnostic performances of lncRNA, miRNA, mRNA and lncRNA-miRNA-mRNA network in ceRNA, receiver operating characteristic (ROC) analysis were performed. Down-regulated mRNA, EZH2 and SIRT1 which were the identified as hub gene in 3.7, were selected. In lncRNA-miRNA-mRNA ceRNA network, there are multiple upstream miRNA and lncRNA of EZH2 and SIRT1. MiRNAs and lncRNAs associated with neuropsychiatric diseases were selected for ROC analysis (ENSG00000251562, miR-26a-5p) (Table 3). ROC analysis showed an area under the ROC curve (AUC) of 0.8104 for ENSG00000251562, 0.7115 for miR-26a-5p, 0.6307 for EZH2, 0.5837 for miR-22-3p, 0.6795 for SIRT1. The AUC of ENSG00000251562—miR-26a-5p—EZH2 and ENSG00000251562—miR-22-3p—SIRT1 were 0.85 and 0.87, respectively (Fig. 7). The AUC was found to be highest for lncRNA-miRNA-mRNA network than lncRNA, miRNA, mRNA alone.

Table 2 (continued)

mRNA															
CYTH3	CCDC28A	FAM136A	RCN1	KIF1B	ZNF275	CDK13	MECOM	SEPHS1	ARHGAP28	PDPR	CDV3	SIRT1	FBXL19	NME4	
Positive score	-0.404	-0.117	0.029	-0.002	-0.126	-0.303	0.043	0.133	-0.051	0.693	0.005	-0.035	-0.506	0.005	-0.036
	Correlation Coefficient														
p-value	0.369	0.803	0.951	0.997	0.788	0.509	0.927	0.776	0.914	0.084	0.992	0.94	0.247	0.992	0.938
Negative score	-0.179	0.372	-0.448	-0.471	-0.256	-0.258	0.538	-0.609	0.726	-0.31	0.444	0.534	0.35	-0.588	-0.463
	Correlation Coefficient														
p-value	0.7	0.411	0.314	0.286	0.579	0.577	0.212	0.146	0.065	0.498	0.318	0.217	0.442	0.165	0.295
Psychopathology score	-0.426	0.112	-0.361	-0.32	-0.184	-0.511	0.269	-0.181	0.704	-0.037	0.302	0.071	-0.034	-0.319	-0.337
	Correlation Coefficient														
p-value	0.341	0.811	0.426	0.485	0.693	0.241	0.559	0.697	0.078	0.938	0.51	0.879	0.942	0.485	0.46
PANSS score	-0.415	0.199	-0.345	-0.374	-0.253	-0.406	0.368	-0.379	0.626	-0.013	0.317	0.296	0.005	-0.419	-0.358
	Correlation Coefficient														
p-value	0.354	0.669	0.448	0.409	0.585	0.366	0.417	0.401	0.133	0.978	0.489	0.519	0.992	0.349	0.431
mRNA															
BFAR	TJP1	EZH2	PLEKHA1	CHORDC1	BCL9	PHF3	SENP5	COIL	IL13RA1	FAM104A	BTG1	BHLHE40	PRPF38B	SYNCRIP	
Positive score	0.197	-0.264	0.047	0.476	-0.529	0.218	-0.004	0.044	-0.017	0.245	0.306	-0.071	0.207	-0.286	
	Correlation Coefficient														
p-value	0.672	0.568	0.92	0.28	0.222	0.638	0.993	0.926	0.972	0.597	0.504	0.88	0.656	0.534	
Negative score	0.811	-0.096	-0.376	0.762	-0.308	0.059	0.49	-0.467	0.013	-0.014	-0.113	0.217	0.809	-0.257	
	Correlation Coefficient														
p-value	0.027*	0.249	0.837	0.406	0.502	0.9	0.264	0.29	0.977	0.977	0.809	0.64	0.028*	0.577	
Psychopathology score	0.776	-0.329	-0.47	-0.435	-0.616	0.145	0.166	-0.262	-0.067	-0.181	0.024	0.198	0.663	-0.358	
	Correlation Coefficient														
p-value	0.04*	0.471	0.287	0.33	0.141	0.756	0.723	0.571	0.887	0.697	0.959	0.67	0.104	0.431	
PANSS score	0.761	-0.37	-0.228	-0.36	-0.57	0.121	0.403	-0.36	0.031	-0.006	0.025	0.131	0.75	-0.354	
	Correlation Coefficient														
p-value	0.047*	0.414	0.623	0.428	0.182	0.797	0.37	0.428	0.948	0.989	0.958	0.78	0.052	0.436	

Table 2 (continued)

mRNA															
	TFAP2A	CREBZF	PIP4K2B	MTF2	POGK	ADAM15	SLC20A1	OSBPL11	TRIM41	PURB	DLG5	RANBP2	LARP1	PPARGC1B	KAT6B
Positive score	Correlation Coefficient	-0.457	-0.227	-0.44	0.17	0.287	0.044	0.136	-0.008	0.295	0.702	0.144	0.413	-0.076	0.45
	p-value	0.303	0.625	0.324	0.715	0.532	0.926	0.771	0.987	0.52	0.079	0.758	0.357	0.871	0.312
Negative score	Correlation Coefficient	0.072	0.406	-0.302	0.119	0.871	-0.174	0.509	0.401	-0.377	0.16	0.041	-0.402	-0.323	0.079
	p-value	0.878	0.366	0.51	0.799	0.011*	0.709	0.243	0.372	0.405	0.733	0.93	0.371	0.48	0.866
Psychopathology score	Correlation Coefficient	-0.307	-0.06	-0.68	0.01	0.641	0.022	0.249	0.164	-0.103	0.355	0.014	-0.207	-0.212	0.188
	p-value	0.504	0.899	0.093	0.984	0.121	0.963	0.59	0.725	0.825	0.435	0.977	0.656	0.649	0.686
PANSS score	Correlation Coefficient	-0.246	0.151	-0.541	0.081	0.763	-0.079	0.393	0.246	-0.192	0.416	0.066	-0.172	-0.293	0.238
	p-value	0.594	0.746	0.21	0.863	0.046*	0.867	0.383	0.595	0.68	0.353	0.888	0.712	0.524	0.607
mRNA															
	DDX19B	DHX57	PGRMC2	COL1A2	TRUB1	NPNT	MAT2A	USP38	CHD7	CAMTA1	QARS	HECTD4	MSL2	KIAA1551	PDIK1L
Positive score	Correlation Coefficient	0.371	0.257	-0.137	-0.182	0.253	0.242	-0.036	-0.077	-0.275	-0.459	0.473	0.311	0.427	-0.4
	p-value	0.412	0.578	0.77	0.696	0.585	0.601	0.939	0.87	0.551	0.3	0.284	0.497	0.339	0.373
Negative score	Correlation Coefficient	0.032	-0.079	-0.089	-0.591	-0.836	0.618	0.548	-0.485	-0.055	-0.096	0.815	0.59	0.401	-0.019
	p-value	0.945	0.867	0.85	0.163	0.019*	0.139	0.203	0.27	0.907	0.838	0.025*	0.163	0.373	0.968
Psychopathology score	Correlation Coefficient	0.261	0.084	-0.187	-0.636	-0.363	0.598	0.29	-0.305	-0.238	-0.231	0.858	0.601	0.338	-0.149
	p-value	0.572	0.858	0.688	0.125	0.423	0.156	0.527	0.506	0.607	0.619	0.014*	0.154	0.459	0.75
PANSS score	Correlation Coefficient	0.225	-0.005	-0.153	-0.602	-0.524	0.59	0.411	-0.338	-0.121	-0.26	0.868	0.632	0.464	-0.222
	p-value	0.628	0.992	0.744	0.152	0.227	0.163	0.36	0.458	0.796	0.573	0.011*	0.128	0.294	0.632

Table 2 (continued)

		mRNA							
		ULK1	SOC54	FGD6	DCUN1D3	MAP3K5	LTN1	MFAP3L	
Positive score	Correlation Coefficient	0.006	-0.17	0.302	0.457	-0.158	0.526	-0.239	
	p-value	0.99	0.715	0.511	0.303	0.735	0.225	0.605	
Negative score	Correlation Coefficient	0.791	0.204	-0.042	-0.588	-0.305	0.199	0.059	
	p-value	0.034*	0.66	0.928	0.165	0.506	0.669	0.9	
Psychopathology score	Correlation Coefficient	0.744	0.006	0.013	-0.149	-0.146	0.306	-0.116	
	p-value	0.055	0.99	0.978	0.75	0.754	0.505	0.804	
PANSS score	Correlation Coefficient	0.713	0.072	0.036	-0.269	-0.237	0.344	-0.002	
	p-value	0.072	0.878	0.939	0.559	0.609	0.45	0.996	

* p-value<0.05




Fig. 5 Go functional annotation and KEGG pathway enrichment analysis for mRNA. Bubble plot of BP (a), MF (b) and KEGG pathway analysis (c) of down-regulated mRNAs in lncRNA-miRNA-mRNA. Bubble plot of BP (d), MF (e) and KEGG pathway analysis (f) of up-regulated mRNAs in lncRNA-miRNA-mRNA. From blue to red, the enrichment increases. Larger circles indicates more significant proportion of genes

Discussion

The study of biomarkers for SZ has attracted much attention, and exosomes have shown potential as biomarkers in a variety of diseases. Exosome-derived circRNAs, miRNAs, proteins, and metabolites have been reported in SZ. It's reported there are 44 differentially expressed exo-circRNAs in SZ patients' and HCs' plasma, which played roles in pathogenesis regarding metabolic process, stress response, and histone ubiquitination [27]. Du et al. performed miRNA expression profiling in serum-derived exosome from first-episode SZ and HCs, and found 11 miRNAs in serum exosomes which can be used to classify samples from SZ patients and HCs and could be promising biomarkers for SZ [14]. Rnganathan et al. examined the neuropathology relevant protein in exosomes from SZ patients and found that GFAP significantly increased and α -II-spectrin significantly decreased in SZ patients compared with HCs [28]. Du et al. identified 25 metabolites in SZ patients which can be used to classify samples from SZ patients and HCs [29]. However, exosomal lncRNA, and exosomal lncRNA-miRNA-mRNA network have not reported yet. In this study, we reported that there are 746 differently expressed lncRNA, 22 differently expressed miRNA, and 2637 differently expressed mRNA (Fig. 2), and performed the ceRNA network analysis.

CeRNAs in exosomes have also been reported, such as malignant tumors [30], endometriosis [31], and ventricular

septal defect [32], exosomal ceRNAs play physiological roles in these diseases and have the potential to serve as biomarkers. In this study, we construct exosomal lncRNA-miRNA-mRNA network based on the interaction between different expressed lncRNA, miRNA and mRNA, which included 8 down-regulated lncRNA, 7 up-regulated miRNA and 65 down-regulated mRNA and 129 edges (Fig. 4), and 1 up-regulated lncRNA, 1 down-regulated miRNA, 4 up-regulated mRNA and 5 edges (Fig. 4). In the ceRNA network, ENSG00000251562, BFAR, HECTD4, CHORDC1, POGK, PRPF38B and ULK1 was positively correlated with PANSS score. TRUB1 was negatively correlated with negative score (Table 2). It is reported that higher astrocyte-derived exosomal P-T181-tau levels were associated with worse executive functioning in SZ [33], implying exosomal genes expression levels were associated with clinical severity. However, none of miRNAs were associated with PANSS (Table 2), this may due to the relatively small sample size (10 patients). In future studies, we will expand the sample size and further examine the correlation between miRNA expression level and PANSS score. Then we explore the GO and KEGG pathway of mRNA in network, and found that the up-regulated mRNA enriched in peripheral nervous system neuron differentiation, peripheral nervous system neuron development in BP (Fig. 5d). However, the down-regulated mRNA didn't enriched in neuropsychiatric related pathway in MF, BP and KEGG pathway (Fig. 5a-c).




Fig. 6 PPI network of down-regulated mRNAs in lncRNA-miRNA-mRNA. The size of the node represents the degree

Table 3 lncRNA and miRNA related diseases

Type	Gene symbol	Related diseases	References
lncRNA	ENSG00000251562	bipolar disorder	[18]
	ENSG00000253352	Cervical cancer, Prostate cancer, Bladder Cancer	[19–21]
	ENSG00000273026	Not reported	
	ENSG00000228223	Not reported	
	ENSG00000270103	Not reported	
miRNA	miR-26a-5p	Parkinson's disease Alzheimer's disease	[22, 23]
	miR-26b-5p	Bladder cancer, Pulmonary cancer, Multiple myeloma	[24–26]

To better analyze the 65 down-regulated mRNAs, we performed PPI network analysis and identified two hub genes, EZH2 and SIRT1 (Fig. 6). Subsequently, we performed ROC analysis on these two genes and their ceRNA.

Enhancer of zeste homolog 2 (EZH2) plays important roles in development and function of central nervous system (CNS). The timely expression of EZH2 maintained a balance of neural stem cell (NSC) self-renewal and

differentiation, whereas removal of EZH2 inhibits NSC proliferation. Furthermore, EZH2 regulated NSC fate determination, in which enhanced EZH2 drives NSC progression toward neuronal and oligodendrocyte lineages at the expense of astrocytes [34]. The upstream miRNA of EZH2 was miR-26a-5p and miR-26b-5p. Mir-26a-5p has been identified as a miRNA associated with inflammation in a variety of pathological processes. Duarte et al. reported that miR-26a-5p is involved in the process of astrocyt-derived small extracellular vesicles regulating dendritic complexity [35]. Mir-26a-5p plays important roles in Parkinson's disease and Alzheimer's disease [22, 23]. At present, most of the reports on miR-26b-5p are concentrated in the field of cancer [24–26], and there is no report in the field of psychiatry. So we selected the miR-26a-5p for ROC curve detection. The four upstream lncRNA of miR-26a-5p: ENSG00000251562, ENSG00000253352, ENSG00000273026 and ENSG00000228223. ENSG00000251562 was reported involved in bipolar disorder [18]. ENSG00000253352 was reported involved in cervical cancer [19], prostate cancer [20] and Bladder Cancer [21]. No disease have been reported for ENSG00000273026 ENSG00000228223. In addition, the expression level of ENSG00000251562 was positively correlated with the negative score and PANSS score (Table 2), so ENSG00000251562 was selected to perform the ROC




Fig. 7 ROC curves of lncRNA, miRNA, mRNA and lncRNA-miRNA-mRNA network. **a** ENSG00000251562, miR-26a-5p, EZH2. **b** ENSG00000251562, miR-22-3p, SIRT1. **c** ENSG00000251562—miR-26a-5p—EZH2. **d** ENSG00000251562—miR-22-3p—SIRT1. ROC analysis expressed as area under the curve (AUC)

curve detection. Our results showed that the EZH2 was down-regulated, miR-26a-5p was up-regulated, ENSG00000251562 was down-regulated in plasma exosomal derived from SZ (Fig. 4), implying that the exosomes play important role in proliferation, growth and differentiation of CNS [36, 37].

Sirtuin (SIRT1) plays essential role in regulating cell survival, apoptosis, inhibiting the stress-induced inflammatory response [38], regulating biological rhythm and transducing dopaminergic signals [39]. Wang et al. reported that SIRT1 gene is associated with SZ in Eastern Asian populations, especially in Japanese and Chinese Han populations [40]. Low plasma SIRT1 mRNA levels are associated with depressive symptoms in SZ patients [41]. subsequently, Wang et al. reported that SIRT1 mRNA level was correlation with rs3758391,

a SNP in SIRT1, and rs3758391 is a risk factor for SZ pathogenesis, especially associated with depressive symptoms [40]. Lee et al. reported that after SIRT1 was inhibited in mice with the inhibitor nicotinamide, mice developed a phenotype of dopamine deficiency, small size, weight loss, and decreased motor activity, suggesting an effect of SIRT1 on the dopaminergic system [42]. The upstream miRNA of SIRT1 has been reported in SZ. Saud et al. reported that miR-22-3p up-regulated in the blood of SZ patients compared with HC [43]. JieMa et al. reported that miR-22-3p, miR-92A-3p and miR-137 found could be used in combination as biomarkers of SZ, and the target genes of miR-22-3p, miR-92a-3p and miR-137 are related to synaptic structure and function [44]. The upstream lncRNA of miR-22-3p ENSG00000270103 has not been reported in

psychiatric disorders. So the ENSG00000251562 was selected as the upstream of miR-22-3p in subsequently analysis. In this study, SIRT1 was down-regulated, miR-22-3p was up-regulated, ENSG00000251562 was down-regulated in plasma exosomal derived from SZ (Fig. 4), implying that exosomes may participate in dopaminergic signaling pathway and thus participate in the regulation of SZ.

ROC analysis was performed on the above lncRNAs, miRNAs and mRNAs and their networks, and found that the AUC of lncRNA-miRNA-mRNA network was higher than lncRNA, miRNA and mRNA alone (Fig. 7). Liu et al. reported that The EGR1—miR-30a-5P—NEUROD1 axis possessed greater diagnostic value than miR-30a-5p alone [45], suggesting that multimolecular networks are better candidates for diagnostic markers than individual molecules.

Exosomes, characterized by their ability to cross the blood–brain barrier, can be used as drug delivery carriers to enter the brain. Curcumin-primed exosomes could prevent the neuronal death to relieve the symptoms of Alzheimer's disease by inhibiting phosphorylation of the Tau protein through activating the AKT/GSK-3 β pathway [46]. Haney et al. have developed a novel exosomal-based delivery system for a potent antioxidant catalase for the treatment of Parkinson's disease (PD). After intranasal administration, catalase-loaded exosome (exoCAT) can accumulate significantly in the brain of PD mouse and play a significant neuroprotective role in both in vivo and in vitro models of PD [47]. Engineered extracellular vesicle carrying circDYM can be delivered to the brain, improved depression-like behavior in mouse models of chronic unpredictable stress (CUS) and inhibiting neuroinflammatory signaling and microglial activation [48]. Exosomes as a drug delivery system for the treatment of SZ has not been reported. The role of exosome lncRNA-miRNA-mRNA ceRNA network in SZ and whether the engineered exosomes can alleviate or prevent the symptoms of schizophrenia are a promising subject, and we will continue to pay attention to this area in future studies.

Conclusion

We constructed lncRNA-miRNA-mRNA ceRNA network in plasma exosomes derived from FOS patients and HCs, and examined the diagnostic performances found that lncRNA-miRNA-mRNA network had the potential to be used as a biomarker for FOS. In future studies, we will expand the sample size to further verify the expression of genes in ceRNA, the binding and regulatory effects of lncRNA on miRNA and miRNA on mRNA in ceRNA network also need to be further verified.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12888-023-05052-9>.

Additional file 1.

Acknowledgements

We appreciate the 136 Medical Rejuvenation Project of Shanxi Province, and YinXu Biotechnology Ltd. Co. (Shanghai, China). The authors would like to thank Hongbao Cao, who helped in revising the paper for English language and the people (volunteers and employees) who participated in this study.

Authors' contributions

Xinzhe Du, Sha Liu and Yong Xu designed the study and wrote the manuscript. Xinzhe Du, Jinzhi Lv, and Ruifang Zhang recruited the subjects. Xinzhe Du, Jinzhi Lv, Jianping Feng, Xinrong Li and Yao Gao analyzed the data. Xinzhe Du, Jianping Feng, Zhiyong Ren, Xiao Wang, Wentao Zhao and Xiaohua Cao revised the manuscript.

Funding

This work was funded by a grant from the National Natural Science Foundation of China (grant numbers 81971601 to Yong Xu, 82271546 to Sha Liu), Shanxi Scholarship Council of China(2022–190 to Sha Liu), Fundamental Research Program of Shanxi Province (20210302123450 to Sha Liu, 202203021212038 to Xinzhe Du) and Scientific Research Project of Health Commission of Shanxi Province (2021045 to Xinzhe Du).

Availability of data and materials

The datasets used and/or analyzed during the current study were upload to GEO database (GSE228881).

Declarations

Ethics approval and consent to participate

This study was approved by the Research Ethics Committee of the First Hospital of Shanxi Medical University, and written informed consents were obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Psychiatry, First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, China. ²Shanxi Key Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental Disorder, First Hospital of Shanxi Medical University, Taiyuan, China. ³Department of Physiology, Shanxi Medical University, Taiyuan, China. ⁴Female Department of Schizophrenia, Shanxi Province Mental Health Center/Taiyuan Psychiatric Hospital, Taiyuan, China. ⁵Department of Psychiatry, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.

Received: 12 October 2022 Accepted: 25 July 2023

Published online: 21 August 2023

References

1. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. *JAMA Psychiat*. 2020;77(2):201–10.
2. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, Yu Y, Kou C, Xu X, Lu J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. *Lancet Psychiatry*. 2019;6(3):211–24.
3. Marwaha S, Johnson S. Schizophrenia and employment - a review. *Soc Psychiatry Psychiatr Epidemiol*. 2004;39(5):337–49.

4. Zhang T, Fang Y, Wang L, Gu L, Tang J. Exosome and exosomal contents in schizophrenia. *J Psychiatr Res*. 2023;163:365–71.
5. Lai CY, Scarr E, Udawela M, Everall I, Chen WJ, Dean B. Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics. *World J Psychiatry*. 2016;6(1):102–17.
6. Safari MR, Komaki A, Arsang-Jang S, Taheri M, Ghafouri-Fard S. Expression pattern of long non-coding RNAs in schizophrenic patients. *Cell Mol Neurobiol*. 2019;39(2):211–21.
7. Sabaie H, Moghaddam MM, Moghaddam MM, Ahangar NK, Asadi MR, Hussien BM, Taheri M, Rezazadeh M. Bioinformatics analysis of long non-coding RNA-associated competing endogenous RNA network in schizophrenia. *Sci Rep*. 2021;11(1):24413.
8. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell*. 2011;146(3):353–8.
9. Fan CN, Ma L, Liu N. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. *J Transl Med*. 2018;16(1):264.
10. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. *Science*. 2020;367:eaa06977.
11. Gao P, Li X, Du X, Liu S, Xu Y. Diagnostic and therapeutic potential of exosomes in neurodegenerative diseases. *Front Aging Neurosci*. 2021;13:790863.
12. Huo L, Du X, Li X, Liu S, Xu Y. The emerging role of neural cell-derived exosomes in intercellular communication in health and neurodegenerative diseases. *Front Neurosci*. 2021;15:738442.
13. Tavakolizadeh J, Roshanaei K, Salmaninejad A, Yari R, Nahand JS, Sarkarizi HK, Mousavi SM, Salarinia R, Rahmati M, Mousavi SF, et al. MicroRNAs and exosomes in depression: Potential diagnostic biomarkers. *J Cell Biochem*. 2018;119(5):3783–97.
14. Du Y, Yu Y, Hu Y, Li XW, Wei ZX, Pan RY, Li XS, Zheng GE, Qin XY, Liu QS, et al. Genome-wide, integrative analysis implicates exosome-derived MicroRNA dysregulation in schizophrenia. *Schizophr Bull*. 2019;45(6):1257–66.
15. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res*. 2000;28(1):27–30.
16. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci*. 2019;28(11):1947–51.
17. Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res*. 2023;51(D1):D587–92.
18. Jovcevska I, VideticPaska A. Neuroepigenetics of psychiatric disorders: focus on lncRNA. *Neurochem Int*. 2021;149:105140.
19. Liu J, Wu D, Lin X, Hong Y, Wang X, Zheng C, Wu Z, Hong Y, Lv Y. Long non-coding RNA TUG1 sponges microRNA-381-3p to facilitate cell viability and attenuate apoptosis in cervical cancer by elevating MDM2 expression. *Life Sci*. 2021;267:118902.
20. Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, Rinn JL, Lee MG, Chen Y, Kantoff PW, et al. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. *Nat Commun*. 2016;7:10982.
21. Yu G, Zhou H, Yao W, Meng L, Lang B. lncRNA TUG1 promotes cisplatin resistance by regulating CCND2 via epigenetically silencing miR-194-5p in bladder cancer. *Mol Ther Nucleic Acids*. 2019;16:257–71.
22. Liu Y, Wang L, Xie F, Wang X, Hou Y, Wang X, Liu J. Overexpression of miR-26a-5p suppresses tau phosphorylation and A β accumulation in the Alzheimer's disease mice by targeting DYRK1A. *Curr Neurovasc Res*. 2020;17(3):241–8.
23. Chen W, Hou C, Wang Y, Hong L, Wang F, Zhang J. Circular RNA circTLK1 regulates dopaminergic neuron injury during Parkinson's disease by targeting miR-26a-5p/DAPK1. *Neurosci Lett*. 2022;782:136638.
24. Miyamoto K, Seki N, Matsushita R, Yonemori M, Yoshino H, Nakagawa M, Enokida H. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. *Br J Cancer*. 2016;115(3):354–63.
25. Wu T, Chen W, Liu S, Lu H, Wang H, Kong D, Huang X, Kong Q, Ning Y, Lu Z. Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p. *FEBS Lett*. 2014;588(12):2107–14.
26. Jia CM, Tian YY, Quan LN, Jiang L, Liu AC. miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. *Pathol Res Pract*. 2018;214(9):1388–94.
27. Tan G, Wang L, Liu Y, Zhang H, Feng W, Liu Z. The alterations of circular RNA expression in plasma exosomes from patients with schizophrenia. *J Cell Physiol*. 2021;236(1):458–67.
28. Ranganathan M, Rahman M, Ganesh S, D'Souza DC, Skosnik PD, Radhakrishnan R, Pathania S, Mohanakumar T. Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia. *World J Biol Psychiatry*. 2022;23(1):33–45.
29. Du Y, Chen L, Li XS, Li XL, Xu XD, Tai SB, Yang GL, Tang Q, Liu H, Liu SH, et al. Metabolomic identification of exosome-derived biomarkers for schizophrenia: a large multicenter study. *Schizophr Bull*. 2021;47(3):615–23.
30. Mao M, Zhang J, Xiang Y, Gong M, Deng Y, Ye D. Role of exosomal competitive endogenous RNA (ceRNA) in diagnosis and treatment of malignant tumors. *Bioengineered*. 2022;13(5):12156–68.
31. Wu J, Huang H, Huang W, Wang L, Xia X, Fang X. Analysis of exosomal lncRNA, miRNA and mRNA expression profiles and ceRNA network construction in endometriosis. *Epigenomics*. 2020;12(14):1193–213.
32. Yang H, Yang S, Shen H, Wu S, Ruan J, Lyu G. Construction of the amniotic fluid-derived exosomal ceRNA network associated with ventricular septal defect. *Genomics*. 2021;113(6):4293–302.
33. Lee EE, Winston-Gray C, Barlow JW, Rissman RA, Jeste DV. Plasma levels of neuron- and astrocyte-derived exosomal amyloid β 1–42, amyloid β 1–40, and phosphorylated tau levels in schizophrenia patients and non-psychiatric comparison subjects: relationships with cognitive functioning and psychopathology. *Front Psych*. 2020;11:532624.
34. Li D, Wang HL, Huang X, Gu X, Xue W, Xu Y. Identification and functional characterization of a new splicing variant of EZH2 in the central nervous system. *Int J Biol Sci*. 2019;15(1):69–80.
35. Luarte A, Henzi R, Fernandez A, Gaete D, Cisternas P, Pizarro M, Batiz LF, Vilalobos I, Masalleras M, Vergara R, et al. Astrocyte-derived small extracellular vesicles regulate dendritic complexity through miR-26a-5p activity. *Cells*. 2020;9:930.
36. Stronati E, Conti R, Cacci E, Cardarelli S, Biagioni S, Poiana G. Extracellular vesicle-induced differentiation of neural stem progenitor cells. *Int J Mol Sci*. 2019;20:3691.
37. Bahram Sangani N, Gomes AR, Curfs LMG, Reutelingsperger CP. The role of extracellular vesicles during CNS development. *Prog Neurobiol*. 2021;205:102124.
38. Rahman S, Islam R. Mammalian Sirt1: insights on its biological functions. *Cell Commun Signal*. 2011;9:11.
39. Kim HD, Hesterman J, Call T, Magazu S, Keeley E, Armenta K, Kronman H, Neve RL, Nestler EJ, Ferguson D. SIRT1 mediates depression-like behaviors in the nucleus accumbens. *J Neurosci*. 2016;36(32):8441–52.
40. Wang D, Tang W, Zhao J, Fan W, Zhang Y, Zhang C. A comprehensive analysis of the effect of SIRT1 variation on the risk of schizophrenia and depressive symptoms. *Front Genet*. 2020;11:832.
41. Fang X, Chen Y, Wang Y, Ren J, Zhang C. Depressive symptoms in schizophrenia patients: a possible relationship between SIRT1 and BDNF. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;95:109673.
42. Lee JY, Ahn K, Jang BG, Park SH, Kang HJ, Heo JI, Ko YJ, Won MH, Tae-Cheon K, Jo SA, Kim MJ. Nicotinamide reduces dopamine in postnatal hypothalamus and causes dopamine-deficient phenotype. *Neurosci Lett*. 2009;461:163–6.
43. Asmaa Mohammed Saud, Ahmed BA. Micronas HAS-MIR-22–3P and HAS-MIR-125B–5P as diagnostic biomarkers of psychotic disorders. *Ann Trop Med Public Health*. 2019;22:62–77.
44. Ma J, Shang S, Wang J, Zhang T, Nie F, Song X, Heping Z, Zhu C, Zhang R, Hao D. Identification of miR-22-3p, miR-92a-3p, and miR-137 in peripheral blood as biomarker for schizophrenia. *Psychiatry Res*. 2018;265:70–6.
45. Liu S, Zhang F, Shugart YY, Yang L, Li X, Liu Z, Sun N, Yang C, Guo X, Shi J, et al. The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. *Transl Psychiatry*. 2017;7(1):e998.
46. Wang H, Sui H, Zheng Y, Jiang Y, Shi Y, Liang J, Zhao L. Curcumin-primed exosomes potentially ameliorate cognitive function in AD mice by

inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3beta pathway. *Nanoscale*. 2019;11(15):7481–96.

47. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. *J Control Release*. 2015;207:18–30.
48. Yu X, Bai Y, Han B, Ju M, Tang T, Shen L, Li M, Yang L, Zhang Z, Hu G, et al. Extracellular vesicle-mediated delivery of circDYM alleviates CUS-induced depressive-like behaviours. *J Extracell Vesicles*. 2022;11(1): e12185.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

